Pneumococcal Polysaccharide Vaccine (PPSV23)7
The PPSV23 is another vaccine that offers protection against a variety of serotypes of S. pneumoniae. The serotypes it covers include: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F.
The PPSV23 vaccine formulation is different from the PCV vaccines. It does not combine the bacterial capsule sugars with the diphtheria CRM197 protein. Without this protein carrier, there is no immune memory, unlike with the PCV vaccines8. Therefore, while PPSV23 provides coverage against more serotypes, it does not offer lifetime protection.
Now that you know the types of pneumococcal vaccine in the Philippines, it’s important to assess your risk. Answer this short screener now:
Who Is Eligible for a Pneumococcal Vaccine in the Philippines?
In an ideal world, everyone should be vaccinated against pneumococcal infections and other preventable diseases. As part of the childhood vaccination schedules, both local and international, PCV is highly recommended. In the Philippines, PCV13 is currently used for routine vaccination.
Children Under 2 Years
As part of routine vaccination, PCV13 is given in 4 doses. Children are eligible for the PCV vaccines starting at the age of 6 weeks, though generally the first dose is given at 2 months old. The following doses are given at 4 months, 6 months, and then at 12-15 months.
Children and Adults (6 to 64 years old)
For children and adults between 6 and 64 years old who have never received a PCV vaccine, one dose can be given. This group should receive the vaccine if they have cochlear implants, cerebrospinal fluid (CSF) leaks, asplenia, or compromised immunity9.
The PPSV23 vaccine can be given in addition to the PCV13 vaccine in adults and children over 2 years old. But it cannot be given to children under 2 years because they will not develop an effective immune response7.
The Elderly (65 years and older)
As of 2019, the Advisory Committee on Immunization Practices (ACIP) states that PCV13 can be given to adults 65 years and older who do not have immunocompromising conditions, CSF leaks, or cochlear implants10.